Terns Pharmaceuticals, Inc. — Director's Dealing 2022

Nov 28, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Terns Pharmaceuticals, Inc. (TERN)
CIK: 0001831363
Period of Report: 2022-11-23

Reporting Person: LAV Biosciences Fund V, L.P. (10% Owner)
Reporting Person: Hopewell Resources Holdings Ltd (10% Owner)
Reporting Person: LAV Aqua Ltd (10% Owner)
Reporting Person: Oriental Spring Venture Ltd (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-11-23	Common Stock	S	1000000	$5.50	Disposed	405583	Indirect
2022-11-23	Common Stock	S	333334	$5.50	Disposed	1059523	Indirect
2022-11-23	Common Stock	S	166666	$5.50	Disposed	529762	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	1286698	Indirect

Footnotes

F1: Shares held by LAV Biosciences Fund V, L.P.

F2: LAV Corporate GP, Ltd. is the general partner of LAV GP III, L.P., which is the general partner of the parent entity of Hopewell Resources Holdings Limited and Oriental Spring Venture Limited. LAV Corporate IV GP, Ltd., is the general partner of LAV GP IV, L.P., which is the general partner of the parent entity of LAV Aqua Limited. LAV Corporate V GP, Ltd., is the general partner of LAV GP V, L.P., which is the general partner of LAV Biosciences Fund V, L.P. Dr. Yi Shi is the managing partner of LAV Corporate GP, Ltd., LAV Corporate IV GP, Ltd., and LAV Corporate V, L.P. and has all voting and investment power with respect to shares beneficially held by each of Hopewell Resources Holdings Limited, Oriental Spring Venture Limited, LAV Aqua Limited and LAV Biosciences Fund V, L.P. Dr. Yi Shi is a managing partner at Lilly Asia Ventures.

F3: Shares held by Hopewell Resources Holdings Limited.

F4: Shares held by Oriental Spring Venture Limited.

F5: Shares held by LAV Aqua Limited.